Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals Long Term Debt: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ALNY Long Term Debt Rankings
| Overall | 99th percentile | 1 of 4657 |
| Sector | 99th percentile | 1 of 525 in Healthcare |
| Industry | 99th percentile | 1 of 163 in Biotechnology |
ALNY Long Term Debt Range, Past 5 Years
| Minimum | 0.00 | Dec 2008 |
| Maximum | 4.906M | Jun 2007 |
| Average | 0.7714M |
About Long Term Debt
Long-term debts are financial obligations and loans lasting longer than one year. A company must report long-term debt on its balance sheet with its date of maturity and interest rate.
Bonds and debt obligations with maturities greater than one year are examples of long-term debt. Other types of securities, including short-term notes and commercial papers usually are not long-term debt because their maturities typically are shorter than one year.
Learn More
You may also be interested in these ALNY related companies
ALNY News
Alnylam Pharma (ALNY) Reports Phase 1 Trial Results Show Proof of Concept for ALN-TTR01
May 10, 7:23AM Street Insider
May 10, 7:23AM Street Insider
Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Focused on Development
May 04, 9:11AM Street Insider
May 04, 9:11AM Street Insider
Listen to $ALNY Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3f0z
about 24 days ago by earningscast
about 24 days ago by earningscast
Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss
May 03, 4:07PM Street Insider
May 03, 4:07PM Street Insider
Just closed out $GNTX $FCFS longs, $KMB $ALNY shorts for 5-day mkt neutral return of 3%!
about 26 days ago by TrendExhaustion
about 26 days ago by TrendExhaustion
Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results
Apr 26, 4:00PM Business Wire
Apr 26, 4:00PM Business Wire
Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board
Apr 23, 8:00AM Business Wire
Apr 23, 8:00AM Business Wire
Listen to $ALNY at biocentury & thomson reuters future leaders in the biotech in - live at 10:00 AM, ondemand after - http://stks.co/3R0H
about 37 days ago by earningscast
about 37 days ago by earningscast
Alnylam (ALNY) Reports Statiscally Significant Data from ALN-PCS Phase I
Apr 20, 8:43AM Street Insider
Apr 20, 8:43AM Street Insider
Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference
Apr 13, 4:00PM Business Wire
Apr 13, 4:00PM Business Wire
Alnylam to Webcast Presentation at 11th Annual Needham Healthcare Conference
Mar 27, 4:00PM Business Wire
Mar 27, 4:00PM Business Wire
Alnylam Retains Key Claims for Kinesin Spindle Protein RNAi Patent in Interference Proceedings
Mar 14, 6:50AM Benzinga
Mar 14, 6:50AM Benzinga
Alnylam Retains Key Claims for Kinesin Spindle Protein (KSP) RNAi Patent in Interference Proceedings
Mar 14, 6:50AM Business Wire
Mar 14, 6:50AM Business Wire
Breakout candidate: $ARWR http://stks.co/2l0W Other RNAi companies: $ALNY $TKMR
about 79 days ago by Xatta_Trading
about 79 days ago by Xatta_Trading
Alnylam to Webcast Presentation at Barclays Capital Global Healthcare Conference
Mar 06, 4:00PM Business Wire
Mar 06, 4:00PM Business Wire
Alnylam to Webcast Presentation at Cowen and Company 32nd Annual Health Care Conference
Feb 29, 4:00PM Business Wire
Feb 29, 4:00PM Business Wire
$ALNY New 52 Week High - Crossed daily highs resistance. Next resistance 13.76 from 10/27/2010.
about 90 days ago by TradeIdeasQuant
about 90 days ago by TradeIdeasQuant
Market Wrap Video + Additions to Watch List http://stks.co/2RIw including: $ALNY $PXP $DMND $CRZO $NU
about 101 days ago by StockTiger
about 101 days ago by StockTiger
Market Wrap Video + Additions to Watch List http://stks.co/2Qqj including: $ALNY $PXP $DMND $CRZO $NU
about 102 days ago by StockTiger
about 102 days ago by StockTiger
Listen to $ALNY Q4 2011 earnings call (EPS -0.33 vs est -0.32) - live at 04:30 PM, ondemand after - http://stks.co/2Krr
about 108 days ago by earningscast
about 108 days ago by earningscast
$ALNY Reports Q4 EPS $(0.33) vs $(0.32) Est; Revenues $20.50M vs $20.90M Est
about 108 days ago by Benzinga
about 108 days ago by Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALNY | 10.43 | +0.00 | +0.00% | 540.59M |
| ALN | 1.25 | -0.04 | -3.10% | 43.09M |
| ALLT | 23.89 | -0.31 | -1.28% | 714.79M |
| AMTD | 17.24 | +0.19 | +1.11% | 9.458B |
| AMTC | 0.1999 | +0.00 | +0.00% | 0.6797M |
| AMT | 65.75 | -0.10 | -0.15% | 25.89B |
| AMSWA | 8.00 | +0.01 | +0.13% | 210.72M |
| AMSG | 27.47 | -0.30 | -1.08% | 859.26M |
| AMSF | 27.18 | +0.08 | +0.30% | 493.32M |
| AMSC | 3.73 | -0.08 | -2.10% | 191.80M |
